Non-arteritic anterior ischemic optic neuropathy

Summary

Non-arteritic anterior ischemic optic neuropathy (MONDO:0000499) is a disease and 10 clinical trials. Top therapeutic interventions include cenegermin and methylprednisolone. A subtype of anterior ischemic optic neuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-arteritic anterior ischemic optic neuropathy
Mondo ID	MONDO:0000499
Orphanet	415300
DOID	DOID:0050864
ICD-11	8640162
UMLS	C1852242
MedGen	338887
GARD	0027534
Is cancer (heuristic)	no

Also known as: NAION · non-arteritic aion

Disease family

This is a subtype of anterior ischemic optic neuropathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › optic nerve disorder › anterior ischemic optic neuropathy › non-arteritic anterior ischemic optic neuropathy

Related subtypes (1): arteritic anterior ischemic optic neuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
PHASE2	2
PHASE1	2
Not specified	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03046693	PHASE4	COMPLETED	Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT07453888	PHASE3	NOT_YET_RECRUITING	Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT02341560	PHASE2/PHASE3	TERMINATED	Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT02439866	PHASE3	UNKNOWN	Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy
NCT00813059	PHASE2	UNKNOWN	Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy
NCT03715881	PHASE2	UNKNOWN	NAION Treatment With Oral Prednisolone and Erythropoietin Injection
NCT07290244	PHASE1	RECRUITING	Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
NCT01064505	PHASE1	COMPLETED	Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
NCT00140491	Not specified	COMPLETED	Vision Restoration Therapy (VRT) to Treat Non-Arteritic Anterior Ischemic Optic Neuropathy
NCT02019927	Not specified	COMPLETED	Electric Stimulation of the Eye to Improve Vision After Trauma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CENEGERMIN	4	1
METHYLPREDNISOLONE	4	1